A new combination haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants.

Journal article

We conducted a phase 3 randomized controlled trial looking at the immunogenicity and safety of a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine, Hib-MenC-TT in a 2-, 3-, and 4-month primary infant immunization schedule. SBA MenC titers > or =1:8 and anti-PRP concentrations > or =0.15 microg/mL were measured in 99.2% and 100%, respectively, of the infants receiving Hib-MenC-TT.

Authors: Pace, D; Snape, M; Westcar, S; Hamaluba, M; Yu, L

• Publication status: Published
• Journal: Pediatric infectious disease journal
• Volume: 26
• Issue: 11
• Pages: 1057-1059
• Publication date: 2007-11-01
• DOI: 10.1097/inf.0b013e31813429fa
• EISSN: 1532-0987
• ISSN: 0891-3668
• Language: English
• Keywords: Haemophilus influenzae type b; Neisseria meningitidis, Serogroup C; Vaccines, Conjugate; Diphtheria-Tetanus-Pertussis Vaccine; Immunization; Haemophilus Vaccines; Meningococcal Vaccines; Vaccines, Combined; Humans; Meningococcal Infections; Immunization Schedule; Poliovirus Vaccine, Inactivated; Tetanus Toxoid; Antibodies, Bacterial; Haemophilus Infections; Infant